

## PharmaEngine News Release

### Poster Presentation of PEP02 at the 2011 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

Taipei, Taiwan, November 11, 2011 -- PharmaEngine, Inc. announced today that their licensing partner Merrimack Pharmaceuticals, Inc. will present a poster for PEP02 (also known as MM-398) at the 2011 American Association for Cancer Research (AACR)/National Cancer Institute (NCI)/European Organization for Research and Treatment of Cancer (EORTC) International Conference on Molecular Targets and Cancer Therapeutics. It will take place during November 12-16, 2011, in San Francisco, California, USA.

The following is the information of the poster to be presented:

**Title:** Identifying differential mechanisms of action for MM-398/PEP02, a novel nanotherapeutic encapsulation of irinotecan

**Poster Session:** Topoisomerase Inhibitors

**Number:** C207

**Date/Time:** Tuesday, Nov 15, 2011, 12:30 PM – 2:30 PM

**Location:** West Hall, Level One, Moscone Center West

#### About PEP02

PEP02 is a novel, stable nanotherapeutic encapsulation of irinotecan. PharmaEngine owns the exclusive right to develop and commercialize PEP02 in Taiwan. In 2003, PharmaEngine licensed in the exclusive rights to develop and commercialize PEP02 in Asia from Hermes BioSciences, Inc., and subsequently expanded the territory to Europe in 2005. Hermes retained the rights in North America and all other territories. Hermes BioSciences, Inc. was acquired by Merrimack Pharmaceuticals, Inc. in 2009. In May 2011, PharmaEngine and Merrimack executed a License and Collaboration Agreement under which PharmaEngine granted back to Merrimack the rights to develop, manufacture, and commercialize PEP02 (known under the designation of MM-398 by Merrimack) in Asia and Europe, with the exception of Taiwan. The U.S. Food and Drug Administration (FDA) granted PEP02/MM-398 orphan drug status for use in the treatment of pancreatic cancer.

#### About PharmaEngine

PharmaEngine, Inc. is a biopharmaceutical company established in Taipei, Taiwan in 2003. PharmaEngine adopts the business model of “no research, development only” and focuses on the development of new drugs for the treatment of cancer and Asian prevalent diseases. For further information, please visit the Company's website at <http://www.pharmaengine.com>.

Contact: Peter Wu, Senior Manager, Business Development, [peter.wu@pharmaengine.com](mailto:peter.wu@pharmaengine.com), Tel. No. (+886)-2-2515-8228.